# Melanotan 2 Research: Studies, Mechanism, and the Sparse Human Record > Melanotan 2 research, summarized and cited: the pigment cascade, the three-volunteer pilot, the erectile-dysfunction crossover, rodent appetite work, and the safety case reports. A grave reading of the pigment mechanism, the small human studies, the rodent work, and the case reports — every quantitative claim cited. ## Start here Melanotan 2 research is unusual: the mechanism is well mapped, but the human evidence is tiny. The studies that matter come in four kinds. First, the pigment science — how the peptide tells skin to darken. Second, two small human studies from the 1990s, one on tanning and one on erections, with only three and ten people. Third, a large body of rodent work on appetite, energy, and erectile signaling that explains the effects but was never done in people. Fourth, a growing stack of case reports — single-patient stories of harm — covering kidneys, muscle, prolonged erections, and changing moles. Read together, they show a peptide that does powerful, real things, on an evidence base far thinner than the tan would suggest. The doses below are reported as facts of those studies, never as a guide. ## Melanotan 2 tanning: the pigment science Activating MC1R on the melanocyte (the pigment cell) raises intracellular cyclic AMP and drives the PKA-CREB-MITF cascade, upregulating tyrosinase (the rate-limiting enzyme of pigment synthesis) and shifting output toward dark eumelanin — skin and hair darkening without UV exposure [8]. Preformulation work characterized Melanotan 2 as a cyclic heptapeptide analog of alpha-MSH being evaluated for prevention of sunlight-induced skin cancers, with an octanol/water partition coefficient of 2.82 at pH 7.35 and an oral bioavailability of only 4.6% in the rat — a physicochemical profile that forces a parenteral (injected) route [7]. The full mechanism is laid out on the [melanotan 2 mechanism of action](/mechanism-of-action) page. ## The human pilot: three volunteers In a single-blind, alternating-day, placebo-controlled pilot Phase I study in three healthy male volunteers, subcutaneous Melanotan 2 (escalated from 0.01 to 0.025-0.03 mg/kg, dosed every other weekday for two weeks) increased facial, upper-body, and buttock pigmentation in two of three subjects after only five low doses [1]. The same five doses produced spontaneous penile erections lasting one to five hours and mild nausea, with dose-limiting somnolence at 0.03 mg/kg; the authors recommended 0.025 mg/kg/day for subsequent Phase I work [1]. This is the foundational human pigmentation study — and it is, in scale, almost the whole of it. These figures are study-design facts; Melanotan 2 has no approved human use. ## The erectile-dysfunction crossover In a double-blind, placebo-controlled crossover study in ten men with psychogenic erectile dysfunction, subcutaneous Melanotan 2 (0.025 mg/kg) produced clinically apparent erections in eight of ten men; mean duration of greater-than-80% tip rigidity was 38.0 minutes with Melanotan 2 versus 3.0 minutes with placebo (p = 0.0045), with transient nausea, stretching, and yawning that required no treatment [2]. This established the central, brain-mediated nature of the erectile effect — it does not depend on the vascular plumbing that conventional treatments target. ## The rodent record: appetite, energy, and the brain The deeper effects were mapped in animals. In male C57BL/6J mice, bilateral microinjection of Melanotan 2 into the nucleus accumbens (0.1-1 nmol per side) significantly decreased food consumption and decreased appetitive responding to gain access to food, without producing taste aversion or changing metabolic rate [5]. In diet-induced obese rats, central Melanotan 2 reduced food intake and body weight and improved insulin sensitivity beyond pair-fed controls [6]. Intravenous Melanotan 2 in rats induced Fos expression in the supraoptic and paraventricular hypothalamic nuclei and increased the activity and secretion of oxytocin neurons — central machinery that may underlie its behavioral effects [29]. And in RAW264.7 macrophages, Melanotan 2 rapidly induced p38 phosphorylation and cyclic-AMP accumulation, with interleukin-10 output abolished by a PKA inhibitor, confirming that its melanocortin signaling runs chiefly through the cyclic-AMP/PKA pathway [30]. ## Melanotan ii in the recent literature Melanotan II remains a core pharmacological tool. A 2024 review of recommended tool compounds for the melanocortin receptors describes Melanotan II (MTII) as a synthetic derivative of alpha-MSH that, alongside the linear analog and the antagonist SHU9119, is used to study melanocortin-receptor physiology, listing pigmentation among the receptor family's roles [31]. A 2026 case report documents reversible oral-mucosal pigmentation in a man who self-administered Melanotan 2 over 64 days — brown pigmentation on the gingiva and buccal mucosa that began to fade weeks after he stopped [33] — one of the most recent published safety reports. ## The case reports: the cited harms The harm literature is built from single patients. A nephrology review reported renal infarction most likely attributable to Melanotan 2, proposing both a thrombotic and a direct toxic renal mechanism, and noted prior reports of rhabdomyolysis and renal failure [4][16]. Priapism recurs across reports, including after apparent overdose [17][18][19]. Eruptive and dysplastic moles, darkening of existing ones, and frank melanoma have all been reported in melanotan users [9][10][11][12][13]. None of these is a controlled trial; together they form a consistent, sobering signal. The whole picture is read out, plainly, on the [Melanotan 2 effects](/effects) page. --- A cinematic reading of one peptide's published record — its light and its shadow, cited; not a clinic, not a vendor, not a prescription.